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Abstract 
Objectives 
To review how health technology assessments (HTA) of medical tests incorporate 
intermediate outcomes in conclusions about the effectiveness of tests on improving health 
outcomes. 
Methods 
Systematic review of English-language test assessments in the HTA database from January 
2005 to February 2010, supplemented by a search of the websites of International Network of 
Agencies for Health Technology Assessment (INAHTA) members.  
Results 
149 HTAs from eight countries were assessed. Half evaluated tests for screening or diagnosis, 
a third for disease classification (including staging, prognosis, monitoring), and a fifth for 
multiple purposes. In 71 HTAs (48%) only diagnostic accuracy was reported, while in 17 
(11%) evidence of health outcomes was reported in addition to accuracy. Intermediate 
outcomes, mainly the impact of test results on patient management, were considered in 61 
HTAs (41%). Of these, 47 identified randomized trials or observational studies reporting 
intermediate outcomes. The validity of these intermediate outcomes as a surrogate for health 
outcomes was not consistently discussed; nor was the quality appraisal of this evidence. Clear 
conclusions about whether the test was effective were included in about 60% of HTAs. 
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Conclusions 
Intermediate outcomes are frequently assessed in medical test HTAs, but interpretation of this 
evidence is inconsistently reported. We recommend that reviewers explain the rationale for 
using intermediate outcomes, identify the assumptions required to link intermediate outcomes 
and patient benefits and harms, and assess the quality of included studies.  
Keywords: Assessment, International, Test Evaluation 
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Introduction 
The clinical effectiveness of a new medical test is determined by the extent to which 
incorporating the test into clinical practice ultimately improves patient health outcomes. This 
depends on a series of factors. For example, the clinical effectiveness of positron emission 
tomography (PET) in the assessment of patients with head and neck cancer for radiotherapy 
depends on its accuracy to delineate the tumour, changes in the radiotherapy regimen 
following PET, and consequences of these changes on patient survival and quality of life (19).  
Randomized controlled trials (RCTs) of tests that capture the entire clinical pathway between 
testing and health outcomes provide direct evidence of the clinical effectiveness of a test. 
Although ideal, these studies are not often done and are sometimes not feasible (4). For fast 
evolving technologies like medical tests, reviewers will rarely find direct trial evidence and 
therefore must often rely on evidence about test accuracy and other factors to draw 
conclusions about clinical effectiveness. 
Within the test evaluation framework of Fryback and Thornbury (7), these factors can be 
regarded as critical steps along the clinical pathway linking the use of the test to patient health 
outcomes (Figure 1). Diagnostic accuracy is a measure of how well a test identifies patients 
with and without a disorder, commonly reported as test sensitivity and specificity (5). For the 
purpose of this report, we have defined the direct consequences of test results, such as 
changes in therapeutic decisions, that can have downstream consequences for health 
outcomes, as ‘intermediate’ test outcomes. Health outcomes refer to measurement of the 
health state of patients, which are ideally measured in treatment RCTs (17).  
All these outcomes are relevant in the assessment of medical tests. Information from studies 
investigating test accuracy can sometimes be directly linked with health outcomes from RCTs 
showing that treatment for the target condition is effective to draw conclusions about the 
health benefits of detecting disease (15). This requires that the spectrum of disease defined by 
the new test is representative of cases included in the treatment RCTs. 
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If test accuracy and health outcomes cannot be directly linked, studies reporting intermediate 
outcomes — those occurring between accuracy and health outcomes — may provide 
additional information to strengthen conclusions about the effectiveness of a new test (Figure 
1). Studies of intermediate outcomes may demonstrate that the test information has an impact 
on clinical decision-making, for example, by changing decisions about treatment or about the 
ordering of further tests. An observational study of 71 patients with head and neck cancer 
showed that PET changed the management plan for 32% of patients (70% when additional 
lesions were detected by PET, 11% when there were no additional lesions) (24). Clearly, this 
change in management plan does not by itself provide evidence of improved health outcomes. 
Hence, studies on intermediate outcomes need careful interpretation.  
Current guidelines on conducting and reporting HTAs of medical tests do not provide explicit 
criteria about when to include intermediate outcomes, what assumptions are necessary when 
linking evidence of accuracy with intermediate outcomes and health outcomes, and how to 
assess the quality of primary studies that examine intermediate outcomes (1;6;18;20). Given 
this lack of guidance, we sought to understand how, and to what extent, different test 
outcomes are being incorporated into HTAs in current practice. We document what outcomes 
beyond test accuracy are being used in current HTAs of medical tests when direct evidence of 
health outcomes is lacking. This review focuses on intermediate outcomes and how this 
evidence is interpreted to draw conclusions about the clinical effectiveness of new tests. 
 
Methods 
Identification of HTA reports 
We first searched the websites of HTA organizations that are INAHTA members to identify 
English-language test assessments published between January 2005 and February 2010 
(search date, 12 February 2010). This pilot search confirmed the wide range of approaches in 
current test evaluation and helped refine the extraction of the data.  
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For the main review we then searched the HTA database (http://www.crd.york.ac.uk/crdweb) 
for test evaluations with a sensitive search strategy using the terms diagnos* OR test* AND 
english:la (search date, 25 March 2010). We included test HTAs with a primary focus on test 
accuracy, intermediate outcomes, and/or patient health outcomes. Reviews of outcomes 
peripheral to our study, such as patient or clinician confidence and testing or screening 
compliance, were not examined further. To be eligible for our review, HTAs had to be reports 
of human studies with a full report in English. We excluded methodological reviews, horizon 
scanning studies, newsletters, pure economic studies, reviews comparing different generations 
of the same technology, and guidelines for tests already used in clinical practice.  
Assessment of HTA reports 
We extracted general information about the name of the test, the proposed role of the test, the 
disease and patient group to be tested, and outcomes mentioned for each eligible HTA. 
Reports were classified according to the type of investigated test: screening (asymptomatic 
populations) (9); diagnosis (detecting or excluding disorders in symptomatic populations) 
(13); disease classification in patients with established diagnosis (including staging, 
prognosis, monitoring) (8;22); or combinations of these purposes. Where more than one 
research question, indication, or test was included in an HTA, the first indication identifying 
studies on intermediate outcomes was used. All included HTAs were independently reviewed 
by two investigators (SD, LS).  
We compiled descriptive statistics of the frequencies of the types of tests, disease areas, and 
the types of reported outcomes in the HTAs. Where applicable, we classified the reported 
intermediate outcomes and summarized the kinds of primary studies on intermediate 
outcomes and how the quality of these studies was assessed. We also examined how this 
evidence was interpreted in the HTAs to support conclusions about the clinical effectiveness 
of the test. HTAs were classified as providing clear conclusions if they made a clear positive 
or negative statement about the clinical effectiveness based on the evidence presented or if 
they judged there was not enough evidence to support definitive conclusions. HTAs were 
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classified as not providing a clear conclusion about clinical effectiveness if they did not 
provide any statement about the likely impact of the test on health outcomes or did not state 
that the evidence available was insufficient for these conclusions. 
Results 
Characteristics of identified HTA reports 
We identified 318 non-duplicate records. Ninety-seven of these were excluded because the 
main focus was not test evaluation; 38 did not present data on accuracy, intermediate 
outcomes or patient health outcomes; 22 were horizon scanning reports or economic 
evaluations; and 12 were guidelines for tests already in use.  
The included 149 HTAs were prepared by 18 agencies in eight countries. The types of tests 
evaluated were for screening (24%), diagnosis (25%), disease classification of established 
diagnosis (32%), or multiple purposes (19%). The most common disease areas were oncology 
(38%) and the circulatory system (17%), followed by endocrine and metabolic diseases (6%), 
infectious diseases (5%), and multiple disease areas (6%) (Table 1). Additional information 
and weblinks to all included HTAs are available in Supplementary Table 1. 
Accuracy 
Seventy-one of the 149 included HTAs (48%) reported solely on diagnostic accuracy. In 42 
(59%) of these assessments we found a clear conclusion about the clinical effectiveness of the 
test. These conclusions were negative (that is, the test was not effective) in 19 assessments 
and positive (the test was effective) in 16, while in the remaining 7 assessments the authors 
argued that there was not enough evidence to support definitive conclusions about the 
effectiveness of the test to improve health outcomes.  
Patient health outcomes 
In addition to accuracy, evidence of patient health outcomes was reported in 17 HTAs (11%). 
Common outcomes were treatment success, disease progression, and treatment complication 
rates. Thirteen of the 17 HTAs (76%) had clear conclusions about the clinical effectiveness of 
  7 
the test. These conclusions were positive in 6 HTAs and negative in one. In 6 HTAs it was 
concluded that evidence for final conclusions about the clinical effectiveness of the test was 
lacking.  
Intermediate outcomes 
A total of 61 HTAs (41%) identified intermediate outcomes that were deemed relevant to 
answer the reviewers’ research question. Of these, 14 did not identify any primary studies but 
included a theoretical discussion of intermediate outcomes. In the remaining 47, primary 
studies reporting on intermediate outcomes were included. Change in patient management 
was reported in 33 HTAs (70%) and was by far the most common intermediate outcome 
(Table 2). Measures of patient management included changes in medication (dose, time to 
discontinuation), surgical procedures (surgery avoided, postponed, or added), radiotherapy 
(target field, dose), ordering of further tests, hospitalization rates, duration of treatment, and 
referral to specialists.  
Other intermediate outcomes reported were downstream patient adherence to other 
interventions (e.g. motivation to cease smoking or lose weight, mammography uptake), 
impact of testing on subsequent visits to health services or hospital admissions, change in 
definitive diagnosis or reducing the number of differential diagnoses, and impact on time 
delays (time to diagnosis, time to transfer to operative care, length of hospital stay).  
In 33 HTAs (70%), at least some of the included studies reported intermediate outcomes in 
sufficient detail to allow an interpretation of test consequences in the clinical pathway. For 
example, these studies did not simply mention that patient management was changed, but 
specified what changes occurred by reporting rates of patients in whom surgery was avoided 
or chemotherapy increased. However, only 17 HTAs included studies that compared 
intermediate outcomes according to test results, for instance, differences in measured time to 
diagnosis between test positives and negatives.  
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Design and quality assessment of primary studies on intermediate outcomes 
Studies that reported intermediate outcomes included randomized trials of tests and 
observational studies. In 21 HTAs, RCTs were included that measured intermediate outcomes 
as the primary endpoint. In 14 of these HTAs, trials also reported health outcomes. In 12 
HTAs, observational diagnostic before-after designs (10) were included to provide evidence 
about intermediate outcomes. These studies compared planned patient management before 
and after test results had been made available to clinicians. In 14 HTAs other observational 
studies were included, of which 5 compared the consequences of testing, such as hospital 
admission rates, with the rates of historic controls before the test was in use.   
The quality of studies on intermediate outcomes was considered in 34 of the 47 HTAs. In 14 
HTAs the authors used published quality-rating tools to assess intermediate outcomes. Some 
of these tools had originally been developed for diagnostic accuracy studies (e.g. QUADAS 
(26): 4 HTAs), some for randomized trials of clinical interventions (e.g. Jadad scale (12): 10 
HTAs). In 13 HTAs the authors adapted existing tools for diagnostic accuracy studies for the 
appraisal of intermediate outcomes. In 7 HTAs the authors developed their own quality-
assessment tools, for example checklists based on recommendations by Guyatt et al (10). The 
results of the quality assessment were clearly reported in 30 HTAs. 
Interpretation of the evidence of intermediate outcomes 
Of the 47 HTAs that identified studies of intermediate outcomes, 17 mentioned in the 
methods section a specific test evaluation framework or guidelines describing how evidence 
from different outcomes was integrated. The Fryback and Thornbury framework (7) was 
mentioned in 5 HTAs, while 12 Australian HTAs cited the MSAC Guidelines (18) for the 
assessment of diagnostic technologies. Furthermore, 9 HTAs applied an overall quality rating 
of the body of evidence to their review. 
The relationship between intermediate and patient health outcomes was considered in 31 
HTAs; however, the uncertainty around assumptions linking intermediate outcomes with 
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health benefits was inconsistently discussed. The validity and limitations of linking patient 
management with health outcomes was discussed in most cases (28 HTAs). In 22 HTAs these 
discussions were at least partly supported with data from included studies on health outcomes, 
but were based on untested assumptions in the other cases. 
Using the evidence of intermediate outcomes, 27 of 47 (57%) HTAs drew clear conclusions 
about the clinical effectiveness of the investigated technology. These conclusions were 
positive in 15 and negative in 7. A lack of evidence to make conclusions was concluded in 5. 
Discussion 
We have reviewed how the international HTA community deals with the challenges of 
evaluating medical tests, with particular focus on the common situation where no direct 
evidence exists that a test improves health outcomes. Half of 149 HTAs reported evidence 
about the consequences of testing beyond accuracy, with 41% considering intermediate 
outcomes. Overall only about 60% of 149 HTAs drew clear conclusions about the clinical 
effectiveness of the test based on the evidence available. Here we will discuss the use of 
evidence of the impact of test results on patient management, the most frequently used 
intermediate outcome, and make recommendations about the interpretation of this evidence in 
HTAs of tests. 
The use of intermediate outcomes is well established in test evaluation frameworks. Fryback 
and Thornbury’s six-tiered model (7) is arguably the most prominent of these frameworks, 
and similar schemes have been proposed (14). They share the basic principle of a hierarchy of 
types of outcome, starting with technical efficacy at the lowest level and then progressing 
sequentially to diagnostic accuracy, diagnostic thinking, therapeutic impact, patient health 
outcomes, and societal aspects. In this hierarchy, therapeutic impact provides higher level 
evidence of test effectiveness than accuracy. When a test has been shown to be accurate and 
its purpose is to improve treatment selection, change in patient management is a necessary 
condition for the test to improve health outcomes. It is, however, not a sufficient condition, 
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because the test result is often only one of several factors influencing patient management, 
and a change of management does not necessarily lead to improved outcomes. Hence, 
intermediate outcomes may help answer some questions about the consequences of testing but 
leave reviewers with open issues about how to judge whether this evidence is an adequate 
surrogate for patient health outcomes. 
To make valid judgments when evaluating change in patient management, we propose a 
structured approach that starts with making a claim about what change in patient management 
will occur as a consequence of the test results and how this is expected to lead to improved 
health outcomes. The type of management change specified and assumptions required to infer 
impact on health outcomes will then inform the formulation of research questions for the test 
HTA (Box 1). This approach is similar to the methodology of realist synthesis developed for 
complex policy interventions (21). Indeed, change in patient management may provide 
important evidence for realist reviews of tests. 
The first consideration is whether evidence of test impact on change in patient management is 
needed for drawing conclusions about the clinical effectiveness of a test. When direct 
evidence of test impact on health outcomes is not available, the value of measuring patient 
management depends on the role the test has in the clinical pathway (3). If a new test is 
proposed to replace a more expensive or invasive existing test without changing practice, 
accuracy may suffice to recommend the new test. For example, evidence of improved or at 
least similar sensitivity of new fecal DNA analyses compared with the common fecal occult 
blood tests in colorectal cancer screening may be enough to recommend the new method, 
provided it is reasonable to assume that a positive test result from the new test will have the 
same consequences on patient management as a positive test from the old test (23).  
When the consequences of test results are not well established, evidence about patient 
management will be relevant for assessment. In these situations, the second step for reviewers 
is to specify what management changes are anticipated and the assumptions required to link 
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the management changes to change in health outcomes (Box 1). These assumptions are 
critical to interpretation of the evidence and ideally should be tested. We found that the key 
assumptions were identified in most HTAs we reviewed but not all. Evidence from published 
studies was often used to support these assumptions. Expert opinion is required to infer 
whether evidence of effective treatment from these studies can be applied to the new setting 
which includes the test in review. In the assessment of PET for head and neck cancer, a panel 
of oncologists and radio-oncologists judged that increased radiotherapy due to PET-detected 
additional lymph node metastases is likely to improve health outcomes based on existing 
evidence of the effectiveness of radiotherapy on cervical lymph node metastases (19). Such a 
judgment needs to weigh up the likelihood and extent of the benefits of changed management 
against its potential harms. However, in many of the reviewed assessments the statements of 
assumptions could not easily be located; they were often somewhat hidden in the discussion. 
We suggest giving this important issue a more prominent place in a dedicated paragraph of 
test HTAs. 
If assumptions that changes in patient management are likely to improve outcomes appear to 
be reasonable, the third step is a review of the evidence for changed management (Box 1). 
Included studies need to report their results with a minimum standard of detail in order to be 
interpretable. Simply reporting a rate of ‘overall change’ is not informative. Information 
about the direction and extent of changed treatment after a positive and negative test result is 
needed to estimate the impact on health outcomes. The assumptions used for these 
conclusions should be explicitly stated as discussed above. Disappointingly, in only about a 
third of reviewed HTAs were the included primary studies sufficiently reported to allow an 
interpretation of changed patient management stratified by test result. Interpretation also 
requires information about test accuracy to determine what proportion of patients receives a 
change in management based on a correct diagnosis and what proportion has management 
changed due to a false positive or false negative test result.  
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In the fourth step, the quality appraisal of this evidence, reviewers have to judge whether the 
included studies are able to demonstrate a true change in patient management (Box 1). The 
different study designs are prone to varying types of bias (25). If these studies do not measure 
actual management in patients randomly allocated to different test strategies, the outcome is 
often a hypothetical assessment of planned management in a patient cohort, so it remains 
unclear to what extent the measured changes in planned management reflect actual clinical 
practice. These limitations always need consideration. We also found inconsistent use of 
different appraisal tools. For a systematic review evaluating the added value of structural 
neuro-imaging with computed tomography or magnetic resonance imaging compared with 
current practice in the assessment of psychotic patients (2), the authors adapted an appraisal 
tool commonly used for accuracy studies (QUADAS) to assess the included diagnostic 
before-after studies. Their subsequent publication of this method (16) is an important step 
towards a more consistent appraisal of these studies. However, the sources of bias relevant to 
accuracy studies, particularly in the verification of test results with the reference standard, do 
not apply to assessing the impact of test information on downstream health outcomes. More 
important are the types of bias encountered in intervention studies, such as differences in 
patient characteristics between tested groups, differences in the measurement of outcomes, or 
differences in the reporting of outcomes (11). In addition, appraisal should include assessing 
the validity of the study authors’ assumptions for inferring that management is a good proxy 
for outcomes. 
Finally, the conclusions of test HTAs should have a clear statement as to whether the use of 
the test is recommended (Box 1). They should also explain whether the test is accurate, 
changes patient management and improves health outcomes; and reviewers should specify on 
what basis the recommendation about the use of the test was drawn. 
This review has some limitations. Because of financial and time restraints we included only 
English-language assessments. We believe that our sample is representative of HTAs in the 
current published English literature, but the extent to which the results can be applied to other 
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HTA settings is debatable. However, the primary aim of this review was to document the 
range of approaches to test evaluation used by different agencies. We believe that the HTAs 
used here are appropriate to document this issue. Some of the information extracted for this 
review was subjective, such as whether conclusions about the effectiveness of tests on 
improving health outcomes were clearly stated. Although two investigators (SD, LS) 
independently rated the included assessments and agreed on a consensus rating in cases of 
initial disagreement, these judgements cannot be fully objective. Finally, in undertaking this 
review, we have presented a framework for test evaluation that has been used by the 
Australian MSAC. We are aware that different agencies may hold slightly different views; we 
anticipate this review will stimulate discussion about the use of intermediate outcomes in 
medical test assessments. In particular, we have identified the need for further research in the 
HTAi community to establish criteria for assessing the quality of primary studies and judging 
the validity of assumptions when using patient management as a surrogate for health 
outcomes. We hope that the recommendations in our Box can be a departure point for these 
discussions.  
In conclusion, we have demonstrated that intermediate outcomes are frequently used in 
medical test HTAs, but interpretation of this evidence is inconsistently reported. We 
recommend that reviewers routinely explain the rationale for using intermediate outcomes to 
investigate a claim about impact on health outcomes, identify the assumptions required to link 
intermediate outcomes and patient benefits and harms, and assess the quality of included 
studies.  
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Figure legends  
Figure 1 
Clinical pathway and determinants of the clinical effectiveness of a medical test: accuracy, 
intermediate outcomes (e.g. patient management) and health outcomes 
Box 1 
Incorporating evidence of test impact on patient management in HTAs of medical tests 
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Table 1. Characteristics of 149 English-language HTAs of medical tests from 18 agencies 
in 8 countries, published Jan 2005-Feb 2010 (details provided in Supplementary Table) 
 
Characteristic n % 
Disease area (ICD 10)   
Infectious diseases (I) 7 5 
Neoplasms (II) 57 38 
Blood (III) 6 4 
Endocrine, metabolic (IV) 9 6 
Mental, behavioural (V) 8 5 
Nervous system (VI) 3 2 
Ear (VIII) 4 3 
Circulatory system (IX) 25 17 
Respiratory system (X) 3 2 
Digestive system (XI) 3 2 
Musculoskeletal system (XIII) 4 3 
Genitourinary system (XIV) 4 3 
Pregnancy, childbirth (XV) 3 2 
Multiple 9 6 
Other 4 3 
Test type   
Screening 36 24 
Diagnosis 37 25 
Classification of established diagnosis* 48 32 
Multiple types 28 19 
Outcomes reported   
Accuracy only 71 48 
Accuracy + patient  health outcomes 17 11 
Accuracy + intermediate outcomes 36 24 
Accuracy + intermediate outcomes + 
patient health outcomes 
25 17 
*includes staging, prognosis, monitoring 
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Table 2. Types of intermediate outcomes reported in primary studies included in 47 
HTAs of medical tests 
Type of intermediate outcome Screening Diagnosis Classification Multiple Total 
Patient management 7 8 13 5 33 
Time to treatment or procedure 3 3 1 1 8 
Downstream patient compliance  3 1 4 0 8 
Health visits, hospital admission rates 1 3 2 0 6 
Change in diagnosis 0 2 3 1 6 
Length of hospital stay 0 1 3 0 4 
Number of potential diagnoses 0 1 0 1 2 
Other 0 1 1 1 3 
Total 14 20 27 9 70 
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Figure 1 
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Box 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Identifying whether the consequences of test results on patient management need to 
be reviewed  
 Specify the consequences of test results for patient management  
 Determine whether these consequences are well defined in existing test 
protocols or whether a review of the evidence is needed 
2. Specifying consequences of patient management for health outcomes 
 Specify test-related changes in patient management that are expected to have 
consequences for health outcomes 
 List key assumptions required to infer these changes in patient management will 
improve health outcomes (e.g. reduced harms through avoidance of invasive 
further tests, improved treatment selection) 
 Discuss the strength of these assumptions and the evidence they are based on 
3. Reviewing patient management studies 
 Include studies that report patient management in sufficient detail: type and 
extent of management changes, contingent on test results 
 Use evidence of test accuracy to report whether the changes are likely to be 
based on correct positive or negative test results 
4. Assessing the quality of included studies 
 Discuss the potential sources of bias of management studies, which include:  
o Reporting of planned (hypothetical) management versus actual management 
o Differences in patient characteristics between tested groups (selection bias) 
o Differences in the measurement of outcomes (detection bias)  
o Differences in the reporting of outcomes (reporting bias) 
5.  Drawing conclusions  
 Indicate whether the test is accurate, changes patient management and improves 
health outcomes  
 Indicate whether the test is recommended and state what evidence this 
conclusion is based on 
